{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:52:04Z","timestamp":1761493924778,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.hbpd.2020.09.007","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T19:11:45Z","timestamp":1601406705000},"page":"507-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"19","author":[{"given":"Si-Si","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Wei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Qing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2020.09.007_bib0001","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0002","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-2006-939751","article-title":"Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment","volume":"26","author":"Hadziyannis","year":"2006","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0005","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0006","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0007","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cgh.2013.09.062","article-title":"Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population","volume":"12","author":"Gordon","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0008","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0009","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B","volume":"36","author":"Lai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0011","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0012","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u00efve patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0013","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3350\/cmh.2017.0003","article-title":"Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir","volume":"23","author":"Jeon","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0014","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0015","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0016","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0017","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2010.01.012","article-title":"Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues","volume":"52","author":"Reijnders","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0018","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/bcp.13330","article-title":"A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study","volume":"83","author":"Yuan","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0019","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/jvh.12623","article-title":"Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance","volume":"24","author":"Lee","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0021","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1128\/AAC.01742-13","article-title":"Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection","volume":"57","author":"Lee","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0022","doi-asserted-by":"crossref","first-page":"10874","DOI":"10.3748\/wjg.v21.i38.10874","article-title":"Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies","volume":"21","author":"Kim","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0023","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0168-8278(12)60012-9","article-title":"Management of treatment failure in chronic hepatitis B","volume":"56","author":"Zoulim","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0024","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2006.11.016","article-title":"Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient","volume":"46","author":"Villet","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0025","article-title":"Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance","author":"Grossi","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0026","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.29187","article-title":"Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial","volume":"66","author":"Lim","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0027","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00535-016-1270-5","article-title":"Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside\/nucleotide analogs","volume":"52","author":"Suzuki","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0028","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2016.08.008","article-title":"Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)\/TDF in lamivudine resistant hepatitis B: a 5-year randomised study","volume":"66","author":"Fung","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0029","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0030","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0031","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01064-18","article-title":"No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection","volume":"62","author":"Cathcart","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0033","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5009\/gnl18183","article-title":"Treatment outcome and renal safety of 3-year tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with preserved glomerular filtration rate","volume":"13","author":"Min","year":"2019","journal-title":"Gut Liver"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0034","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2147\/TCRM.S143286","article-title":"Renal safety of tenofovir and\/or entecavir in patients with chronic HBV monoinfection","volume":"13","author":"Yang","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4254\/wjh.v9.i5.227","article-title":"Adverse effects of oral antiviral therapy in chronic hepatitis B","volume":"9","author":"Kayaaslan","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0036","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.3748\/wjg.v19.i43.7671","article-title":"Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir","volume":"19","author":"Park","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0037","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/jgh.12567","article-title":"Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B","volume":"29","author":"Heo","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0038","article-title":"Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0039","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s00535-013-0864-4","article-title":"Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine","volume":"49","author":"Suzuki","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0040","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0041","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1128\/AAC.48.10.3702-3710.2004","article-title":"Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro","volume":"48","author":"Delaney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0042","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijantimicag.2016.05.016","article-title":"Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-na\u00efve patients with chronic hepatitis B","volume":"48","author":"Boglione","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0043","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3350\/cmh.2016.0019","article-title":"Comparison of the clinical outcomes between antiviral-na\u00efve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment","volume":"22","author":"Kim","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.hbpd.2020.09.007_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajg.2014.01.003","article-title":"Entecavir 1 mg versus combined lamivudine\/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study","volume":"15","author":"Maklad","year":"2014","journal-title":"Arab J Gastroenterol"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387220302046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387220302046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:41:38Z","timestamp":1761493298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499387220302046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1499387220302046"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2020.09.007","relation":{},"ISSN":["1499-3872"],"issn-type":[{"type":"print","value":"1499-3872"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2020.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}